中国药科大学药学院硕导介绍：徐金宜

　　(7)Yi Zeng, Jinyi Xu*, Xiao Ming Wu, et al. The advances in R&D of selective COX-2 inhibitors. Chin. J. New Drug, 2006, 15(6), 410-415.

　　(8)Jinyi Xu, Qianhui He, Xiao Ming Wu, et al. Synthesis and Biological Activities of 4-Substituted-5-Alky-2,4-Dihydro-2-[3-Chloride-4-Fluorophenyl]-3H-1,2,4-Triazol-3-one Deriverivatives. Chin. J. Org. Chem., 2006, 26(1): 123-128.

　　　(9)Jinyi Xu, Hequan Yao, Xiaoming Wu. et al. Synthesis and Anti-inflammatory Activities of Diaryl-Substituted-1,2,4-Trizole Derivatives. J. Chem. Chin. Univ., 2005, 26(12): 2254-2258.

　　(10)Jinyi Xu, Xiaoming Wu. Hua Wei-yi, et al. Synthesis of 5-Amido-1H-imidazo [5,4-b] pyridine Derivatives and their AngiotensinⅡ Receptor Antagonistic Activities. J. Chem. Chin. Univ., 2005, 26(6): 1067-1071.

　　(11)Matsuo K, Kanayama M, Jinyi Xu, et al. Concise Formal Synthesis of (S)-Gregatin B. Heterocycles, 2005, 65(7): 1609-1614.

　　(12)Jinyi Xu, Nianning Ji, Xiaoming Wu, et al. QSAR Studies of AngiotensinⅡAT1 Receptor Antagonists. J. Chin. Pharm. Univ., 2005, 36(2): 99-105.

　　(13)Jinyi Xu, Wu Xiao-ming, Hua Wei-yi, et al. 4/-[(Triazolinone-1-yl) methyl] biphenyl- 2-sulfonamides Derivatives as Dual AngiotensinⅡ/ Endothelin A Receptor Antagonists. Drugs Fut., 2004, 29(Suppl. A): 266-267.

　　(14)Jinyi Yang, Jinyi Xu*, Xiao Ming Wu, et al. Research on the Anti-tumor Natural Products.Chin. J. Mod. Appl. Pharm., 2007, 24(4): 277-282.

　　(15)Bo Jiang, Jinyi Xu*, Xiao Ming Wu, et al. Advances in the Research on the Dual Cyclooxygenase-2(COX-2) and 5-Lipoxygenase (5-LOX) Inhibitors. Chin. J. Mod. Appl. Pharm., 2008, 25(2): 109-114.

　　(16)Jinyi Xu*, Jingyi Yang, Qian Ran, Xiaoming Wu. et al. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg. & Med. Chem. Lett., 2008, 18: 4741-4744.

　　(17)Li Zhi Fu, Jinyi Xu*, He Quan Yao and Xiao Ming Wu. A synthesis of 4H-1, 4-benzothiazines. J. Chem. Res., 2008, (10): 566–567.

　　(18)Jinyi Xu, Bo Jiang, Xiao Ming Wu, et al. Synthesis，anti-inflammatory activities and SAR studies of 1, 5-diarylsubstitued-1, 2, 4-trizoles. Chin. J. Med. Chem. 2008, 18(5), 321-328.

　　(19)Diliang Guo, Jinyi Xu, Hualiang Jiang, and Hong Liu. Efficient Iron-Catalyzed N-Arylation of Aryl Halides with Amines. Organic Letters, 2008, 10, 4513-4516.

　　(20)Bei Yan, Guangji Wang, Xiaoming Wu, Jinyi Xu, et al. Identification of the major metabolites of 1-(2,6-dichlorophenyl)-3-n-butyl-1,4-dihydro-4-{4-[2-(1H-tetrazole-5-yl)-1H- pyrrol-1-yl]phenylmethyl}-5H-1,2,4-triazol-5-one, a newangiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS. Biomed. Chromatog., 2007, 21: 912-924.

　　(21)Bei Yan, Guangji Wang, Xiaoming Wu, Jinyi Xu, et al. Determination of 1-(2,6-dichloro- phenyl)-3-n-butyl-1,4-dihydro-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-5H-1,2,4-triazol-5-one, a newangiotensin type 1 receptor antagonist in rat plasma by LC-ESI-MS: Application to pharmacokinetic studies. Chromatographia, 2007, 66: 55-61.

　　(22)Yu Wang, Qiujuan Wang, Jinyi Xu, et al. [Ca2+]i and PKC-a are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro. Biochemical and Biophysical Research Communications, 2007,364:118-123.

　　(23)Jie Liu, Jinyi Xu *, Xiaoming Wu. et al. Total synthesis and antihypertensive activity of 7, 8-dihydroxy-3-methyl-isochromanone-4. Bioorg. & Med. Chem. Lett., 2009, 19: 1822-1824.